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Abstract
Atrial fibrillation (AF) is the most frequent of all cardiac arrhythmias and it is associated 
with an increased risk of stroke, systemic embolism and heart failure. Patients with AF 
have a twofold increased risk of death and fivefold increased risk of stroke compared 
with those without AF. In patients with heart failure (HF), AF ablation improves left 
ventricular (LV) function over short- and long-term follow-ups, especially compared 
with medical treatment. Furthermore, AF ablation in HF patients relates to a significant 
improvement in quality of life, functional class and exercise tolerance, possibly related to 
the improvement in LV function and hemodynamic status of the patients. Finally, data 
showed that restoration of sinus rhythm in this setting of patients reduced the incidence 
of stroke and death. In this review, we reported all the major data regarding atrial 
fibrillation therapy in patients with heart failure.
Keywords: atrial fibrillation ablation, heart failure, quality of life, left ventricular 
function, atrial fibrosis
1. Incidence and pathogenesis of atrial fibrillation in heart failure
Atrial fibrillation (AF) is defined as a cardiac arrhythmia characterized by the surface ECG 
showing ‘absolutely’ irregular RR intervals and absence of distinct P waves. Irregular atrial 
electrical activity, represented by the “f” waves, may be seen in some ECG leads, most often 
in lead V1, the “f-f” interval is variable and usually shorter than 200 ms [1]. An irregular pulse 
should always raise the suspicion of AF, but an ECG recording is necessary to diagnose AF [1].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
From a clinical point of view, AF can be categorized into five subtypes based on the presen-
tation and duration of the arrhythmia: (1) patient who presents with AF for the first time; 
(2) paroxysmal AF is self-terminating, usually within 48 h, but it may continue for up to 
7 days; (3) persistent AF is present when an AF episode either lasts longer than 7 days or 
requires termination by cardioversion; (4) AF is considered as long-standing persistent when 
the arrhythmia has lasted for ≥1 year; (5) permanent AF, when the presence of the arrhyth-
mia is accepted by the patient (and physician) and when it is decided to adopt a rate control 
strategy [1] (Figure 1).
Atrial fibrillation, the most frequent of all cardiac arrhythmias, is associated with an increased 
risk of stroke, systemic embolism (SE) and heart failure (HF). Patients with AF have a twofold 
increased risk of death and fivefold increased risk of stroke compared with those without 
AF [1–6].
Atrial fibrillation has multiple adverse clinical implications. The loss of atrial systole and the 
irregular, fast heart rate contribute to symptoms such as palpitations and reduced exercise 
tolerance and also predispose to the development of intracardiac thrombus and systemic 
thromboembolism. Atrial fibrillation can also cause tachycardia-mediated cardiomyopathy 
or worsening of preexisting heart failure [3].
Whereas anticoagulation treatment reduced the risk for stroke, large randomized trials failed 
to demonstrate any significant mortality benefit of a pharmacologically based rhythm control 
strategy even in patients with left ventricular dysfunction when compared with a rate control 
strategy [7–11].
Figure 1. European Society of Cardiology guidelines for classification of atrial fibrillation [1].
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This has led to a widespread belief that restoration of sinus rhythm (SR) does not improve 
prognosis. However, in-depth analysis of these trials demonstrated that the restoration of SR 
was associated with a 47% lower risk for death compared with continuing AF.
Besides having a good safety profile, catheter ablation therapy for AF has proved effective 
in establishing and maintaining SR. Induction of AF requires an initiating trigger and per-
petuation occurs because triggering activity is sustained or because of the presence of a sus-
ceptible atrial substrate. Premature atrial ectopy has been shown to be the most frequent 
trigger for AF. Observations in patients with dual-chamber pacemakers revealed that 48% of 
AF  episodes were triggered by premature atrial beats, 33% were preceded by bradycardia and 
17% were sudden in onset [12]. Also, continuous cardiac monitoring in postoperative patients 
demonstrated that supraventricular premature beats induced AF in 72–100% of cases [13].
Endocardial mapping revealed that the origin of ectopic activity initiating AF is located inside 
the pulmonary veins (PV) in 89–94% of cases and that AF is most often triggered by repetitive 
focal PV discharges [14–18].
Catheter ablation targeting the fascicles, which connect the PVs to the left atrium, leads to 
electrical isolation of the PVs. Interestingly, after electrical isolation, up to 58% of PVs dis-
play slow, dissociated activity and some sustain ongoing tachycardia dissociated from the left 
atrium in SR, emphasizing the arrhythmogenic potential of these structures [19, 20].
Indeed, besides being triggers for AF, PVs can also be responsible for the perpetuation of AF. 
In a small series of patients who had irregular focal discharges initiating and perpetuating AF, 
foci at the ostium of PVs were found to be the drivers of sustained AF in 66%. Focal radiofre-
quency (RF) delivery targeting these foci eliminated AF in all these patients [21].
In addition, a spatial gradient in cycle length, with the PVs activating at a higher frequency 
than the nearest atrial tissue, has been found in some patients and this reinforces the role of 
PVs as AF perpetuators [22–25].
The involvement of the PVs in the maintenance of AF was further emphasized by the observa-
tion that PV isolation in paroxysmal AF led to a progressive increase in the AF cycle length, cul-
minating in the termination of AF in 75% of patients. PV isolation rendered AF noninducible in 
57% of patients and prevented relapse in 74% of patients [26]. These findings led to the venous 
wave hypothesis, postulating a role for PVs in maintenance of AF in most patients with par-
oxysmal AF [27]. Later, spectral analysis and dominant frequency mapping revealed that the 
dominant frequency and the highest dominant frequency were spatially distributed near the 
PVs in most of patients with paroxysmal AF [28]. Put together, these observations emphatically 
substantiate the role of PVs in the initiation and maintenance of nonpermanent forms of AF.
Although elimination of PV arrhythmogenicity has been highly effective for paroxysmal AF, 
it has modest efficacy for persistent AF suggesting that mechanisms beyond the PVs also 
contribute to perpetuation of AF in these patients. A number of ablation strategies have been 
proposed: linear ablation, ablation of complex fractionated atrial electrograms, ablation of 
intrinsic cardiac autonomics and ablation of rotors. Frequently these approaches are per-
formed in combination, to target these substrate-related mechanisms beyond the PV arrhyth-
mogenicity, particularly in patients with persistent AF [1].
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In the setting of heart failure, the increased filling pressure of atrial and ventricle contributes 
to the electroanatomic disarrangement of the muscle fibers providing a substrate for reentry 
and imparts electrical heterogeneity and arrhythmogenicity to onset AF. Histological exami-
nations of atrial tissue in patients with AF show patchy fibrosis, which may contribute to the 
nonhomogeneity of conduction. Atrial biopsies from patients undergone to cardiac surgery 
show increase in cell size, loss of sarcoplasmic reticulum and atrial myofibrils, changes in 
mitochondrial shape, accumulation of glycogen granules, alteration in connexin expression 
and increase in extracellular matrix [1]. A multicenter trial has demonstrated that atrial fibro-
sis, as estimated by magnetic resonance imaging (MRI), is independently associated with the 
likelihood of recurrent AF and in particular an extensive fibrosis caused a low success rate 
after catheter ablation [29]. Furthermore, recent studies showed that transmural conduction 
is the predominant mechanism of breakthrough during atrial fibrillation demonstrating the 
substrate complexity of this arrhythmia [30].
Heart failure increases the risk of AF, with the mechanism of the arrhythmia being multi-
factorial. Furthermore, AF is an independent risk factor for the development of heart failure 
and both conditions frequently coexist. Atrial fibrillation in patients with heart failure pre-
disposes to episodes of worsening heart failure and increases the risk of thromboembolic 
events [1]. Hospitalizations due to AF account for one-third of all admissions for cardiac 
arrhythmias. Acute coronary syndrome, aggravation of heart failure, thromboembolic com-
plications and acute arrhythmia management are the main causes. In 30% of patients with 
AF, it is possible to find HF with NYHA II-IV and at the same time, in 30–40% of heart failure 
patients, AF is found. Heart failure can be both a consequence of AF (e.g., tachycardiomy-
opathy or decompensation in acute onset AF) and a cause of the arrhythmia due to increased 
atrial pressure and volume overload, secondary valvular dysfunction, or chronic neurohu-
moral stimulation.
In the past decade, it showed an increase of the incidence of AF, above all in patients with 
HF. Many factors have contributed to these epidemiological changes; first of all, the new 
therapeutic approach to the cardiovascular disease and the following growing average age 
of patients. A recent comparison between two survey showed a significant increase in the 
incidence of AF in patients with HF between 38.4% in 2005 and 50.4% in 2013 [31]. Marked 
unexplained interregional variations in the occurrence of stroke and mortality suggest that 
factors other than clinical variables might be important [31]. Prevention of death from heart 
failure should be a major priority in the treatment of atrial fibrillation.
2. Pharmacological treatment of atrial fibrillation in heart failure
2.1. Rhythm control vs. rate control
The optimal resting ventricular rate in patients with AF and HF could be between 60 and 
100 bpm [32–34]. Van Gelder et al. [35] suggested that a resting ventricular rate of up to 
110 bpm might still be acceptable and 2016 ESC AF guidelines recommend this threshold 
as the target for rate control therapy [33, 36–40], but a lower rate for patients with HF may 
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be preferable (60–100 bpm). The optimal ventricular rate during exercise is also uncertain, 
but may be 110 bpm during light exercise [34].
Sinus rhythm, theoretically, offers physiological rate control, normal atrial activation and 
 contraction, a normal sequence of atrioventricular (AV) conduction and AV valvular function 
and a regular rhythm.
Most clinical trials (PIAF, STAF, RACE, HOT CAFÉ, CABANA and AFFIRM) [1, 9–11, 41, 42] 
have reported no clear superiority of rhythm control. Furthermore, Crijns have reported that 
patients with AF and HF are unlikely to remain in sinus rhythm in the long-term and 2012 
focus updated of ESC guidelines of the management of atrial fibrillation, that rhythm control 
should not be vigorously pursued in this clinical setting [1].
However, a subgroup analysis of AFFIRM reported that rhythm control may be useful in 
patients with left ventricular dysfunction. In this study, patients with depressed left ven-
tricular function benefited significantly from rhythm control compared to rate control. The 
 presence of sinus rhythm was associated with a lower risk of death [43].
2.2. Practical approach to rate control
Rate control in AF is based mainly on pharmacological depression of conduction through the 
AV node. In the presence of HF, this requires careful dose titration and can result in symp-
tomatic bradycardia requiring permanent pacing. Beta-blockers are the preferred drugs in 
combination with digoxin (adjunctive therapy), because they provide optimal rate control 
at rest and during exercise in this setting of patients [1]. The AFFIRM study showed during 
long-term follow-up that beta-blockers achieved optimal rate control in 58% of patients [44]. 
In a subgroup analysis, patients with a history of HF and left ventricular ejection fraction 
<40%, successful rate control was observed with beta-blocker, with or without digoxin in 81% 
and with digoxin alone in 54%, at 1-year follow-up.
Atrioventricular (AV) nodal ablation may be the treatment of choice in the presence of symp-
toms intolerable to higher rates, despite the use of rate slowing agents. Investigators  compared 
pharmacological rate control vs. AV node ablation in 66 patients with CHF and AF [45]. In this 
randomized study, both treatment arms were associated with alleviation of symptoms and an 
increase in functional capacity. Patients treated with the “ablate and pace” strategy had fewer 
symptoms with no changes in cardiac performance and quality of life. This strategy was not 
associated with a reduction of mortality.
2.3. Practical approach to rhythm control
The potential of amiodarone to maintain sinus rhythm in patients with AF and HF has been 
repeatedly shown in observational and prospective randomized controlled studies.
In CTAF study, therapy with amiodarone reduced the incidence of recurrent AF by 57% 
when compared with sotalol and propafenone [46]. In the CHF-STAT study, patients treated 
with amiodarone, converted to sinus rhythm more frequently (31.3% vs. 7.7% on placebo) 
 compared to placebo, experienced fewer recurrences of AF and were less likely to develop 
Transcatheter Ablation of Atrial Fibrillation in Patients with Chronic Heart Failure
http://dx.doi.org/10.5772/67024
107
new AF [47]. Amiodarone is a drug of choice for the management of AF associated with HF. 
In addition to its antiarrhythmic effects, it is useful in controlling ventricular rate response 
during recurrences [47].
Dronedarone is a drug similar to amiodarone, though is devoid of iodine with a theoreti-
cally safer adverse effect profile [1]. In the dronedarone atrial fibrillation study after elec-
trical  cardioversion (DAFNE) trial, dronedarone prolonged the mean interval to recurrence 
of AF by 55% compared with placebo, resulting in the spontaneous conversion to sinus 
rhythm in high percentage of patients. The results of the European trial in atrial fibrillation 
or flutter patients receiving dronedarone for the maintenance of sinus rhythm (EURIDIS) and 
American-Australian-African equivalent ADONIS showed that dronedarone was superior to 
placebo in the prevention of recurrent AF and effective in controlling the ventricular rate in 
over 1200 patients. However, the dronedarone in moderate to severe HF evaluating morbid-
ity decrease (ANDROMEDA) study was stopped prematurely, as an interim safety analysis 
suggested an excess risk of death in patients on active treatment.
3. Ablation of atrial fibrillation in HF patients
Rhythm control with antiarrhythmic drugs has not been shown to confer benefit in random-
ized trials, neither in patients with HF nor in those without HF [7, 8]. The lack of benefits of 
antiarrhythmic drugs might reflect their poor (<50%) efficacy in maintaining sinus rhythm [8]. 
Conversely, ablative treatment in these patients can be highly effective in reducing  morbidity 
and improving quality of life and functional capacity [7–9, 41–52]. However, patients with 
AF and left ventricular ejection fraction have more recurrences after a single procedure, 
thus requiring more repeat procedures, which increase costs and risks [53]. Recent studies 
[54–60] have demonstrated that nonpulmonary vein foci firing from the atrial chambers or 
other  thoracic veins play an important role in initiating and maintaining AF in 3.2–62% of 
patients, depending on age, sex and comorbidities. Patients with HF usually have a more 
complex and diseased atrial substrate harboring more nonpulmonary vein foci, which could 
be responsible for the observed recurrence of AF or atrial tachyarrhythmia AT after pulmo-
nary vein antrum isolation.
In a recent study, Zhao et al. [61] demonstrated that patients with left ventricular ejection 
fraction more often presented nonpulmonary vein triggers than in patients with normal ejec-
tion fraction; in patients with the long-term procedural outcome of pulmonary vein isolation 
ablation alone remain unsatisfactory with a 32.2% single-procedure success rate, whereas 
 pulmonary vein isolation plus nonpulmonary vein triggers ablation significantly increases 
the success rate to 75.0%, which is comparable with the success rate of pulmonary vein isola-
tion alone in patients with normal ejection fraction (75.0% vs. 81.7%).
Patients with low ejection fraction and paroxysmal atrial fibrillation had a higher prevalence 
of nonpulmonary vein triggers than patients with normal ejection fraction (69.1% vs. 26.6%). 
Many investigators [54–60] have addressed the importance of nonpulmonary vein triggers 
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for atrial fibrillation initiation and the reported incidence of nonpulmonary vein triggers in 
paroxysmal atrial fibrillation.
The basis for extensive left atrial ablation lies in the pathophysiology of atrial fibrillation 
itself [62]: atrial fibrillation perpetuating in a left atrium with significant substrate modifica-
tions and advanced structural and electrical remodeling has historically been targeted by lin-
ear lesions [63]. However, linear lesions and CFAE ablation may increase the risk of iatrogenic 
atypical atrial re-entries (flutter) or atrial tachycardias if not transmural, incomplete, or not 
perfectly anchored to electrically inert structures, counterbalancing the benefit derived by 
extensive atrial substrate modification [64].
Among the studies reporting AF ablation in patients with HF, 55% of the patients underwent 
PV isolation alone, with a large heterogeneity among studies (6–89%). None of the observa-
tional studies were designed to compare the efficacy of different AF ablation approaches. 
However, in the meta-analysis by Anselmino et al. [65] including the largest available popu-
lation, there was no difference in AF ablation outcome, performing PV isolation alone when 
compared with additional linear ablation. Moreover, no data compared the different tech-
niques to perform AF ablation (radiofrequency, cryoablation, laser, rotors and surgery) in 
patients with HF. Finally, recent data reported a higher success rate after AF ablation with a 
hybrid approach (percutaneous and surgical), but no data were published regarding patients 
with HF [1].
Larger randomized studies are needed to understand the optimal procedural protocol to 
adopt in patient with HF and symptomatic AF.
3.1. Paroxysmal vs. persistent atrial fibrillation ablation in heart failure
Several studies have suggested that catheter ablation of AF in the context of HF is rela-
tively safe reporting that the complication rate was not different from that in patients with 
structurally normal hearts [7, 48–53, 65–85]. The success rate for catheter ablation of parox-
ysmal AF was similar in HF patients compared with non-HF patients (70–80%), whereas 
the success rate for persistent AF was markedly worse. In randomized studies, the suc-
cess rate following a single procedure has been reported at 38–68%, rising to 50–88% after 
repeated procedures (2 or 3) at 6–12 months [52, 79–81]. Ullah et al [84] published an inter-
national multicenter registry from seven centers for patients with HF undergoing AF abla-
tion (Figure 2). In this study with 1273 patients (171 with HF and 1102 without HF) and a 
median follow up of 3.1 years, the final procedure success rate was no different from par-
oxysmal AF (78.7% vs. 85.7%, p = 0.186), but significantly different for persistent AF (57.3% 
vs. 75.8%, p < 0001).
However, despite a lower success rate in patients with HF ablated for persistent AF, Zhu et 
al. [85] published a meta-analysis of three randomized controlled trials showing a significant 
improvement of LVEF (6.22%) and reduction of NYHA class and Minnesota living with heart 
failure questionnaires scores in patients with HF ablated for persistent AF compared with the 
medical rate control.
Transcatheter Ablation of Atrial Fibrillation in Patients with Chronic Heart Failure
http://dx.doi.org/10.5772/67024
109
The lower success rate for catheter ablation for persistent AF in the HF group is likely multi-
factorial. Both HF and the conditions leading to HF increase the left atrial pressure and wall 
stress that causes progressive mitral regurgitation, which further impacts on left atrial pres-
sure and remodeling. The result of these factors is more scarred and remodeled atria, which 
are more inclined to support AF.
3.2. Improvement in left ventricular function and heart failure
3.2.1. Symptoms after atrial fibrillation ablation
Atrial fibrillation ablations have been shown to improve the LV function during short- and 
long-term follow-up, when compared to medical therapy. Several meta-analyses  regarding 
the usefulness of AF ablation in HF patients have been published [53, 65, 82, 83, 85]. In the 
first two works, including maximum 800 patients, the authors concluded that single AF 
ablation procedure in HF patients is less effective in patients without structural disease, but 
improves including redo procedures, obtaining a significant improvement in LV ejection 
 fraction over follow-up [53, 82]. The third multicenter, collaborative meta-analysis, including 
more than 1800 patients [65], reported over a mean follow-up of 2 years a significant improve-
ment in LV ejection fraction and a reduction in the proportion of patients with severely 
depressed LV function. This finding is very important since potentially confers to ablation the 
ability to reduce the proportion of patients requiring implantation of cardioverter defibrilla-
tors. Moreover, the authors reported that time to first AF diagnosis and heart failure diagnosis 
was significantly related to ablation outcome, highlighting the importance of prompt optimal 
treatment of both HF and AF to achieve the best clinical benefit.
 Figure 2. Freedom from atrial fibrillation and atrial flutter after ablation in patients with and without heart failure [84].
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Ganesan et al. [83], furthermore, reported meta-analyses including more than 900 patients 
with HF-ablated for AF showing a LVEF improvement of 13%.
Ullah et al [84] in their multicentric registry reported a significant LV ejection fraction increas-
ing from 34.4 ± 9 to 45.8 ± 12.8% (p < 0.001).
One small observational prospective study specifically investigated patients with preserved 
LVEF [75]. This study, including 73 patients with a mean follow-up of 34 months, reported 
27% efficacy after the first procedure which further raised to 73% with redo procedures and 
antiarrhythmic drugs. On note, LV diastolic function and systolic function measured with 
strain and strain rate improved only in patients maintaining stable sinus rhythm.
Moreover, data reported that effective sinus rhythm restoration after AF ablation was useful 
to improve LVEF in patients with tachycardiomyopathy [48, 65].
Furthermore, AF ablation in HF patients relates to a significant improvement in quality of life, 
functional class and exercise tolerance, which possibly relates to the improvement in LV func-
tion and hemodynamic status of the patients. In general, shorter history of HF and AF is both 
associated with improved outcome: AF ablation in HF patients should be considered preco-
ciously to avoid progression of atrial substrate alteration. Left atrial dimension is a marker of 
advanced substrate alteration; in fact, patients with severe LA dilation present lower rate of 
sinus rhythm maintenance.
In particular, Ullah et al. [84] reported a reduction in NYHA class from 2.3 ± 0.7 at baseline to 
1.5 ± 0.8 at follow up. This was the first study to examine specifically the impact of maintain-
ing sinus rhythm on rates of stroke and death after catheter ablation of AF patients with HF 
showing that restoration of sinus rhythm reduced the incidence of stroke and death (Figure 3).
 Figure 3. Factors predicting stroke and death in patients with heart failure [84].
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3.3. Indications for transcatheter ablation of atrial fibrillation in patients with heart failure
Within the general population, the safety and efficacy rates of AF ablation promoted this pro-
cedure to the first choice following one antiarrhythmic drug failure and in selected patients, 
even the first option before drugs [1]. Its role within HF, instead, is less well defined due 
to small randomized trials and observational studies [48–53, 65–85]. The revised European 
recommendations for antiarrhythmic drug therapy leave amiodarone as the only available 
antiarrhythmic agent in this setting [1]. In patients who suffer from symptomatic AF recur-
rences on amiodarone therapy, catheter ablation remains as the sole choice for rhythm control 
therapy [1] (Figure 4). In the last guidelines, AF ablation is indicated in symptomatic patients 
with reduced ejection fraction in order to improve symptoms and cardiac function (class IIa, 
level of evidence C) [36].
3.4. Catheter ablation of atrial fibrillation in specific cardiomyopathies populations
Some observational studies reported the outcome of AF ablation among patients with hyper-
trophic [65, 83, 86, 88]. All studies reported low efficacy after a single ablation procedure, 
especially during long-term follow-up. However, the efficacy raised up to 70–80% including 
the over 30% redo procedures and the prevalence of extensive left atrial ablation, including 
linear lesions or CFAEs, which was higher when compared with the general HF population. 
This finding reflects a complex substrate typical of this specific cardiomyopathy, character-
ized by severe left atrial enlargement. Being AF detrimental on both the quality of life and 
prognosis of HCM patients, its effective treatment warrants careful attention and ablation 
may be considered precociously to achieve rhythm control.
 Figure 4. European Society of Cardiology guidelines for atrial fibrillation ablation [1].
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Moreover, although AF standard treatment in valvular cardiomyopathies is more commonly 
surgical, performed concomitantly to heart surgery, some studies reported the outcome of 
AF ablation among patients with significant valvular disease. Two studies, including patients 
with prosthetic valves or previous percutaneous intervention for mitral rheumatic disease, 
reported a very low efficacy after a single procedure, raising up to 70% at a mean follow-up 
of 24 months including over 50% repeated procedures [87, 88]. Other two studies includ-
ing patients with moderate aortic or mitral defects, instead, reported outcomes similar to the 
 general population [87, 89].
3.5. Future perspectives
Catheter ablation of AF is gaining a significant role in HF treatment of patients with concomi-
tant AF, as confirmed by the latest ESC guidelines. However, the following points remains 
of concern. First of all, pulmonary vein isolation alone and/or additional non-PV targets, as 
in the general population, need to be tested in prospective randomized trials on HF patients.
Further studies, moreover, should define the optimal timing to perform AF ablation in these 
patients to increase the success rate and reduce mortality.
In the future, technological innovations may contribute to rise AF ablation safety, for example, 
new irrigated catheters able to significantly reduce the fluid administration during procedure, 
particularly relevant among HF patients.
Finally, due to the complexity of this procedure, the suggestion is to refer to experienced, 
high volume centers, also skilled to manage plausible complications.
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